Its Nottingham site offers spray drying, powder filling and dry powder inhaler technology
The Next Generation Impactor (NGI) is the main analytical tool used by Aesica in the characterisation of inhaled products
Aesica, a contract development and manufacturing organisation (CDMO) headquartered in the UK, intends to increase its inhalation services and products in development and will open a new Lead Technical Centre in the near future.
A key part of the inhalation drive has been the intake of skilled staff alongside the commercial development of several new inhalation technologies. The firm is also actively partnering with other innovative companies and universities to discover and engineer new technologies for commercial applications.
Aesica currently has two new development technologies available to clients, including spray drying techniques delivered through a partnership with Upperton, and a powder filling technology delivered through 3P’s Fill2Weight.
The firm says the plan marks a systemic shift in the market, with clients now looking for CDMOs to have a wider range of development technologies, delivery expertise and the ability to take a project through to commercialisation.
Another key factor in the company’s growth within this market has been the adoption of non IP protected products, which enables Aesica to concentrate with the client on developing the right formulation irrespective of delivery mechanism.
These new technologies have provided advantages to customers in terms of lowering costs, particularly for re-formulations of generic products and Aesica forecasts that this will be a rapidly expanding sector.
Building on these successes the firm is researching new innovations in formulation technologies to complement its services and envisages opening a new inhalation Lead Technical Centre by the end of 2014.
Ian Lafferty, Site Director for Aesica Nottingham, said: 'Inhalation is a rapidly growing market with many US companies looking to bring NCE production to Europe, while we also see a dramatic growth for products going into China and SE Asia, particularly among generic formulations. We have largely operated under the radar in terms of inhalation products despite the wealth of new technologies coming to market here and our intention is to take a lead in bringing products to market faster and developing the next generation of technologies through our Lead Technical Centre.'